Prihlásiť sa Zaregistrujte sa zadarmo

Príjmy spoločnosti Affimed N.V

Aká je hodnota metriky Príjmy spoločnosti Affimed N.V?

Hodnota metriky Príjmy spoločnosti Affimed N.V. je -€75.65

Aká je definícia metriky Príjmy?

Výsledok príjmov pre kmeňových akcionárov (Income) sa rovná celkovému príjmu mínus vyplatené prioritné dividendy.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Príjmy spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Affimed N.V

Čomu sa venuje spoločnosť Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Firmy s metrikou príjmy podobnou spoločnosti Affimed N.V